Atavistik Bio is discovering and designing drugs to restore protein function in disease. Many proteins are regulated through allosteric control by the binding of different metabolites. Atavistik is using this knowledge to identify metabolite-protein interactions that have therapeutic potential. To discover drugs, Atavistik is using their high-throughput platform for unbiased identification followed by structure-aided drug design. The platform is applied to genetically validated targets in metabolic disease and cancer and therefore has the potential to tackle the underlying cause of many diseases. The company is in preclinical stages and believes their novel approach will enable the development of first-in-class drugs.